San Diego-primarily based Viking Therapeutics marked alone as a significant competitor during the weight loss drug market in February following revealing promising data from the mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided as being a weekly injection and in March t